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Abstract
Background: Hematopoietic stem cells mobilize to the peripheral circulation in response to stroke. However, the
mechanism by which the brain initiates this mobilization is uncharacterized.
Methods: Animals underwent a murine intraluminal filament model of focal cerebral ischemia and the SDF1-A pathway was
evaluated in a blinded manner via serum and brain SDF1-A level assessment, Lin2/Sca1+ cell mobilization quantification,
and exogenous cell migration confirmation; all with or without SDF1-A blockade.
Results: Bone marrow demonstrated a significant increase in Lin2/Sca1+ cell counts at 24 hrs (272660%; P,0.05 vs sham).
Mobilization of Lin2/Sca1+ cells to blood was significantly elevated at 24 hrs (6076159%; P,0.05). Serum SDF1-A levels
were significant at 24 hrs (Sham (103614), 4 hrs (94620%, p =NS) and 24 hrs (130617; p,0.05)). Brain SDF1-A levels were
significantly elevated at both 4 hrs and 24 hrs (11367 pg/ml and 112610 pg/ml, respectively; p,0.05 versus sham
76611 pg/ml). Following administration of an SDF1-A antibody, Lin2/Sca1+ cells failed to mobilize to peripheral blood
following stroke, despite continued up regulation in bone marrow (stroke bone marrow cell count: 536665, blood cell
count: 127624; p,0.05 versus placebo). Exogenously administered Lin2/Sca1+ cells resulted in a significant reduction in
infarct volume: 4265% (stroke alone), versus 21615% (Stroke+Lin2/Sca1+ cells), and administration of an SDF1-A antibody
concomitant to exogenous administration of the Lin2/Sca1+ cells prevented this reduction. Following stroke, exogenously
administered Lin2/Sca1+ FISH positive cells were significantly reduced when administered concomitant to an SDF1-A
antibody as compared to without SDF1-A antibody (1064 vs 0.761, p,0.05).
Conclusions: SDF1-A appears to play a critical role in modulating Lin2/Sca1+ cell migration to ischemic brain.
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Introduction
Each year approximately 795,000 Americans experience a new
or recurrent stroke. [1] Increasing levels of circulating Hemato-
poietic Stem Cells (HSC)/Hematopoietic Progenitor Cells (HPC)
have recently been demonstrated to correlate with improved
neurological function following stroke, suggesting a potentially
critical role for HSC/HPC’s in limiting stroke injury and/or
facilitating post-stroke recovery. [2–6] HSC/HPC’s are circulating
bone marrow derived mononuclear cells that reside in the adult
bone marrow and have the unique ability to self renew and
differentiate into multiple lineages. [7] HSC/HPC’s are known to
mobilize to the peripheral circulation from bone marrow in
response to stroke. [8–10] Additionally, it has been suggested that
stroke recovery can be augmented with angiogenic blood vessel
formation. [11] Mobilized HSC/HPC are recruited to the site of
injury and can subsequently contribute to angiogenesis. [11]
Chronic heart disease [12] and hind limb ischemic [13] studies
have shown promising therapeutic results from mobilized HSC/
HPC.
Stromal Derived Growth Factor-1 Alpha (SDF1-A) is localized
to chromosome 10q11.1 [14] and is highly conserved between
species. [15] SDF1-A belongs to the CXC family of chemokines
and was originally described as a pre B cell growth stimulating
factor. [15] SDF1-A is a ligand for CXCR4, a G protein coupled
receptor, and their interaction mediates a chemotactic response
followed by cell migration. [16] CXCR4 is expressed on several
cell types and was the only known receptor for SDF1-A to induce
vasculogenesis, [17] hematopoiesis, [18] chemotaxis, [19] and
metastasis [19] until another receptor, CXCR7 was recently
discovered. [20] SDF1-A and CXCR4 have been shown to
regulate trafficking of HSC/HPC in response to non-cerebral
injury. [21–23] Additionally, hematopoietic stem cells have also
been shown to mobilize from the bone marrow to the blood in
response to injury. [19] De Falco et al. demonstrated that ischemic
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blood vessels in a hind limb ischemia model release SDF1-A,
which, in turn, triggers the mobilization of the HSC from the bone
marrow (a distant healthy niche) to the peripheral blood. [24–27]
Once in the circulation, the HSC can differentiate into myeloid
cells, lymphocytes, erythrocytes, platelets or endothelial progenitor
cells. [28] In the myocardium, [29] HSC/HPC’s have been shown
to home towards SDF1-A released from ischemic regions [27]
where they mature into endothelial cells and contribute to resident
vasculature repair. [19].
SDF1-A is a powerful chemo attractant [30] and is expressed by
several tissues in the body including bone marrow, [31] liver, [32]
kidney [33] and the central nervous system. [34] SDF1-A is
expressed in tissues during development [35] and in adulthood.
[25] SDF1-A has been implicated in the homing of exogenously
administered (IV or direct intraparenchymal injection) bone
marrow derived mesenchymal stem cells (BSMC’s) to ischemic
brain in rats. [36,37] However, the application of these data to
humans was brought into question, when, in a murine model – the
most common species evaluated for many stroke therapeutics,
exogenously administered human BSMC’s failed to ‘home’ to the
ischemic brain. [38] Furthermore, these studies did not evaluate
endogenous HSC/HPC mobilization and the influence of SDF1-A
axis on this mobilization or subsequent potential homing. We
hypothesized that, following murine experimental cerebral ische-
mia, SDF1-A may direct an increased mobilization of HSC/HPC
from the bone marrow to the peripheral blood. The HSC/HPC




Nine-week-old C57/BL/6 male (unless otherwise specified)
mice were obtained from Harlan Laboratories (Tamps, Florida).
This study was carried out in strict accordance with the
recommendation in the guide for the care and use of Laboratory
Animals of the National Institute of health. The protocol was
approved by the Committee on the Ethics of Animal Experiments
of Vanderbilt University (Permit Number: A3227-01). Animals
were kept under specific conditions according to protocols
approved by the Institutional Animal Care and Usage Committee
and all efforts were made to minimize suffering.
Intraluminal Filament Model of Stroke
A heat blunted nylon monofilament 7-0 suture, 11–13 mm in
length was introduced through the external carotid artery and
then into the common carotid where the filament was fed into the
internal carotid artery until it blocked the middle cerebral artery.
Sham animals were treated the same as the experimental animals,
minus introduction of the monofilament suture. Occlusion was
confirmed by laser Doppler flowmetry (Perimed, Ardmore, PA)
and was maintained for 45 minutes. Middle cerebral artery
occlusion was considered to be technically adequate at $80%
reduction in cerebral blood flow was observed immediately
following placement of the occluding catheter. Animal tempera-
ture was carefully controlled using a water heated circulating pad
using a rectal probe (World Precision Instruments, Sarasota, Fl).
Following surgery, animals were scored at time of sacrifice to
obtain neurologic deficit score and confirm cerebral ischemia, as
previously described. [39] An animal with no observable
neurological deficit was given a score of 0; if the animal failed to
extend the contralateral paw, it was given a score of 1; an animal
circling to the right was given a score of 2; if the animal fell over on
the contralateral side when attempting to walk, it was given a score
of 3; if an animal did not exhibit any spontaneous motor activity, it
was given a score of 4.
When evaluated, cerebral infarct volume was calculated using
digital planimetric analysis of 2 mm sectioned 2,3,5-Triphenylte-
trazolium chloride (TTC) stained brains, as previously described.
[39] Briefly, Brain tissue was sectioned coronally at 2 mm intervals
and the sections placed in TTC for 30 minutes at 37uC. Digital
images were obtained for each section and for each section the
area of infarct, area of entire ipsilateral hemisphere and area of
contralateral hemisphere were calculated using Image J. The
respective volumes were then calculated by summing the area of
the values multiplied by the thickness. To obtain the final infarct
volume corrected for edema, the following formula was used:
[contralateral hemisphere volume –(ipsilateral hemisphere vol-
ume-infarct volume)]/contralateral hemisphere6100.
Do Lin2/Sca1+ Cell Levels Respond to Stroke?
Eighteen mice were used as sham controls (4 hours, n = 9; 24
hours, n = 9) and 18 mice underwent surgery (n = 9 for 4 hours;
n = 9 for 24 hours) to evaluate serum and bone marrow HSC/
HPC (Lin2/Sca1+ cells) response to stroke. At the time of
sacrifice, blood from each mouse was harvested along with the
hind leg bones (femurs). The mononuclear cells from the blood
and the bone marrow from the above mentioned cohorts were
washed with a phosphate buffered saline containing 2% fetal
bovine serum (Fisher Scientific, Pittsburg, PA). The washed
mononuclear cell layer from each blood and bone marrow sample
was then re-suspended in buffer and Lin2/Sca1+ selection kits
(Stem Cell Technologies; Vancouver, CA) used to obtain the
Lin2/Sca1+ cells from the samples. The enriched cells were
counted using a hemacytometer (Fisher Scientific; Pittsburg, PA).
Each sample was counted three times. The number of cells
counted was adjusted for volume and reported as total number of
cells obtained for each sample.
Do SDF1-A Levels Increase in Serum and Brain?
Sixteen animals were divided into 3 cohorts (sham (n = 6), 4
hours (n = 5) and 24 hours (n = 5) hours post stroke surgery) for
SDF1-A analysis in serum and brain tissue. Two hundred
microliters of blood was obtained from mice at the 4 and 24-
hour time points. The blood was allowed to clot at room
temperature, spun at 2000 RPM and the serum removed for
analysis by SDF1-A ELISA per manufacturer’s protocol (R&D
Systems, Minnepaolis, MN). Brain tissue was homogenized in
RIPA buffer with protease inhibitors (Pierce Biotechnology,
Rockford, IL) and quantified for protein using a BCA protein
assay (Pierce Biotechnology, Rockford, IL). The homogenized
samples (normalized for protein) were analyzed for SDF1-A levels
using an ELISA per manufacturer’s protocol (R&D Systems,
Minnepaolis, MN).
Does SDF1-A Blockade Prevent Lin2/Sca1+ Cell
Mobilization?
To evaluate the relative contribution of SDF1-A to the Lin2/
Sca1+ cell response, commercially available SDF1-A neutralizing
antibody (100 ug dose; R&D Systems, Minneapolis, MN), or a
PBS (vehicle) control was administered via IP injection one day
prior to surgery and again immediately following surgery.
Eighteen animals were divided into 2 groups (n = 9 each):
stroke+placebo and stroke+SDF1-A antibody. Lin2/Sca1+ cells
were enriched and counted from the bone marrow and blood as
described above.
Mobilization of Stem Cells after Stroke
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Does SDF1-A Blockade Abrogate Homing?
Sixteen mice were divided into stroke+placebo (n= 9) and
stroke+ Lin2/Sca1+ cells (n = 7) cohorts. Another cohort of 14
animals was divided into stroke+SDF1-A antibody+placebo
(n = 9), stroke+SDF1-A antibody+ Lin2/Sca1+ cells (n = 5). For
those animals receiving Lin2/Sca1+ cells injection, the cells were
enriched from a separate group of control mice (n = 24) and
injected IV at reperfusion. Infarct volumes were calculated at 24
hours post stroke.
Furthermore, Lin2/Sca1+ cells were enriched from male
donor mice (n = 16) and injected IV at reperfusion into 2 cohorts
of female mice (stroke+placebo+ Lin2/Sca1+ cells n = 4;
stroke+SDF1-A antibody+ Lin2/Sca1+ cells n = 4). The animals
were sacrificed at 24 hours post stroke and their brain removed for
FISH analysis. For FISH analysis, Paraformaldehyde fixed frozen
mouse brains were cut at 50 um through the area of infarct. Slides
were air dried overnight, washed 265 minutes in PBS and then
rinsed briefly in ddH2O. Antigen retrieval was performed by
immersing slides in 1 M sodium thiocyanate for 30 minutes at
95uC. The slides were removed from the retrieval solution and
rinsed thoroughly in ddH2O before digestion in 4 mg/ml porcine
pepsin (Sigma Aldrich, St Louis, MO) in 1XPBS at pH 2.0 for 10
minutes. Slides were rinsed 1 min in water, 1 min in 2X Saline
Sodium Citrate Buffer (SSC) and then dehydrated in increasing
concentrations of Ethanol before probe was applied. Mouse
chromosome X (orange) and Y (green) were applied to the cells
following the manufacturer’s directions (Cambio Ltd, Cambridge,
UK). Slides were denatured and hybridized using a Hybrite oven
(Vysis, Downer’s Grove, IL) overnight at 37uC. Slides were
washed at 46uC in 50% formamide/2XSSC 3X 7 minutes, in 2X
SSC for 5 minutes and in 4X SSC+0.1% Igepal for 5 minutes.
Slides were permitted to air dry in the dark for 10 minutes before
cover slipping with DAPI Vectorshield (Vector labs, Burlingame,
CA). Slides were documented with an Olympus BX10 Microscope
(Hunt Optics & Imaging, INC., Pittsburg, PA). The number of
male (Y) chromosome positive cells counted and the sum of cells
counted per high power field are shown.
Analysis
The technician performing the surgeries, and all subsequent
analysis, was completed with total blinding to experimental cohort
across all experiments. All statistical analysis was performed using
the Students t-test, Mann-Whitney Test or ANOVA with a post
hoc Newman-Keuls Multiple Comparison test (GraphPad Soft-
ware version 5, Inc. La Jolla, CA, USA). Mean values are reported
as mean6SD, and a p value of less than 0.05 was considered to be
significant and is indicated on subsequent graphs with an asterisk.
Results
Cortical blood flow (CBF) measured using a Trans-cranial
doppler after middle cerebral artery occlusion decreased by at least
80% in all animals. Animals that underwent stroke surgery had a
consistently higher neurological deficit score compared to sham
animals (all sham animals had a neurologic deficit score of 0). For
early (4 hour) stroke cohort analysis neurologic deficit was used to
confirm stroke, as TTC staining is inconsistent at such early
assessments. Across all experiments no significant difference was
observed in the 4 hour versus 24-hour cohorts’ neurological deficit
scores.
Do Lin2/Sca1+ Cell Levels Respond to Stroke?
Analysis of the ability of Lin2/Sca1+ cells to mobilize from the
bone marrow to the peripheral blood following stroke (Figure 1)
demonstrate that, following murine stroke, bone marrow produc-
tion of Lin2/Sca1+ cells was minimal at 4 hours (106646%
versus sham), but achieved a highly significant increase by 24
hours (272660% versus sham). Mobilization of the Lin2/Sca1+
cells to the peripheral blood was also non-significantly elevated at
4 hours (169648% versus sham) and significantly elevated at 24
hours (6076159% versus sham; P,0.05).
Do SDF1-A Levels Increase in Serum and Brain?
ELISA (Figure 2A) demonstrated that the SDF1-A levels in the
mouse serum were not significantly elevated at 4 hours, but were
significantly elevated by 24 hours post ischemia (102614%,
94620% and 130618%, Control, 4 hours and 24 hours
respectively; 4 hrs vs control: P =NS, 24 hrs vs control:
p,0.05). Brain SDF1-A level analysis (Figure 2B) demonstrated
significant elevation at both 4 and 24 hours post stroke
(11367 pg/ml and 112610 pg/ml, respectively; p,0.05 for both
versus control 76611 pg/ml).
Does SDF1-A Blockade Prevent Normal Lin2/Sca1+ Cell
Mobilization?
Lin2/Sca1+ cells failed to mobilize to the peripheral blood
following stroke+SDF1-A antibody (Figure 3), despite continued
up regulation in the bone marrow (bone marrow cell counts with
stroke+SDF1-A antibody: 536665% versus stroke+placebo:
272660%, p,0.05; blood cell counts = SDF1-A antibody:
127624% versus stroke+placebo: 6076159%, p,0.05).
Does SDF1-A Blockade Abrogate Homing?
Administration of exogenous Lin2/Sca1+ cells resulted in a
significant reduction in infarct volume at 24 hours (Figure 4A)
(4265% versus 21615%, stroke+placebo versus stroke+ Lin2/
Sca1+ cells, p,0.05). In contrast, administration of the SDF1-A
antibody concomitant to the injection of exogenous Lin2/Sca1+
cells (Figure 4B) prevented any reduction in infarct volume
(35615 versus 31622%; stroke+SDF1-A antibody+placebo vs
stroke+SDF1-A antibody+ Lin2/Sca1+ cells, p =NS). Further-
more, FISH analysis demonstrated that administration of male
Lin2/Sca1+ cells to female mice upon reperfusion resulted in
identification of Y chromosome positive cells in the ischemic
hemisphere (Figure 5). However, this effect was abrogated when
the male Lin2/Sca1+ cells were administered concomitant to an
SDF1-A antibody (1064 versus 0.761, P,0.05).
Discussion
Recent studies have demonstrated the ability of HSC/HPC to
home to an area of injury (in ischemic hind limb, [40] cardiac
disease [41] and liver [42]). While, the mechanism involved HSC/
HPC recruitment to the area of injury is poorly defined, SDF1-A
has been implicated in the homing process. [22,36,37] The results
of the studies presented herein suggest that recruitment of Lin2/
Sca1+ cells to stroked brain occurs along an SDF1-A pathway.
Lin2/Sca1+ cell counts indicate that bone marrow Lin2/
Sca1+ cell production increased post stroke, followed by Lin2/
Sca1+ cell mobilization to the peripheral blood (Figure 1). Several
studies have shown that Lin2/Sca1+ cells mobilize from the bone
marrow to the peripheral blood in response to injury [27] and that
these cells contribute to recovery. [43] However, the mechanism
involved in mobilization and consequent homing following stroke
has yet to be investigated. We chose to perform evaluations at 4
hours and at 24 hours. These time points were specifically chosen
as 24 hours represents a standard time point across the majority of
murine intraluminal filament studies. Four hours was chosen as it
Mobilization of Stem Cells after Stroke
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reasonably reflects the time window for current Class I evidence
based clinical stroke intervention with IV tPA (with centers using
either a 3 or 4.5 hour window). A more expansive number of time
point evaluations would be of interest and our study is limited by
containing only these two time points, however, logistic and
economic limitations prevented a more detailed time point
analysis.
Once confirmation of Lin2/Sca1+ cell up-regulation and
mobilization was obtained we then sought to determine whether
Lin2/Sca1+ cells navigate to the area of cerebral ischemia in
response to an SDF1-A gradient. Serum SDF1-A levels did not
achieve significance until 24 hours post stroke surgery (Figure 2A).
This correlated well with a significant increase in production in the
bone marrow and mobilization of these cells to the blood at 24
hours. Interestingly, the ischemic hemisphere experienced highly
significant elevations in SDF1-A levels within 4 hours (Figure 3),
providing a temporal indicator that the source of subsequent
serum elevations may be the ischemic brain itself. It may also be
that it is this brain to serum to bone marrow gradient that then
results in Lin2/Sca1+ cell homing to the ischemic hemisphere.
Neutralizing SDF1-A, through administration of an SDF1-A
antibody, prevented mobilization of Lin2/Sca1+ cells from bone
marrow to blood (Figure 3). Leading to the effective sequestration
of Lin2/Sca1+ cells within the bone marrow following stroke and
a significantly reduced number of Lin2/Sca1+ cells in the blood.
However, antibody administration did not prevent continued bone
marrow upregulation. This suggests that initial activation of
Lin2/Sca1+ cell production likely occurs through an alternate
signaling pathway, but that subsequent movement of Lin2/Sca1+
cells from bone marrow to blood, and then from blood to ischemic
hemisphere appears to be dependent upon an SDF1-A. To ensure
these findings are not an unintended epiphenomenon resulting
from alternative effects of the antibody, alternative methods of
SDF1-A abrogation should be evaluated before this phenomenon
can be conclusively tied to an SDF1-A pathway alone. However,
this initial implication is encouraging that an SDF1-A dependent
pathway is critical to Lin2/Sca1+ cell homing following stroke.
Shichinohe et al. provided additional support for the importance
of the SDF1-A pathway when they evaluated parenchymally
injected BSMC migration following rodent stroke. [37] They
observed significant mitigation of the migratory response in
Figure 1. Enumeration of bone marrow and blood Lin2/Sca1+ cell numbers following stroke. (A) Twenty-four hour post stroke mice
show a marked increase in the number of Lin2/Sca1+ cells present in the bone marrow compared to controls. (B) Twenty-four hour post stroke mice
also showed a marked increase in the mobilization of these cells to the blood. * P,0.05.
doi:10.1371/journal.pone.0085615.g001
Figure 2. SDF1-A levels in serum and brain. (A) Serum SDF1-A levels reached significance at 24 hours post surgery. (B) Brain tissue levels of
SDF1-A demonstrated significant elevations at both 4 and 24 hours post stroke compared to sham animals. *P,0.05.
doi:10.1371/journal.pone.0085615.g002
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CXCR4, a major receptor for SDF1-A, knockout mice. [37]
Wang et al. further supported an SDF1-A critical pathway when
they demonstrated that GFP labeled exogenous (IV administered)
BSMCs homed to ischemic brain in rats and that this homing was
abrogated with the administration of a CXCR4 antibody. [36]
However, (1) both of these studies evaluated CXCR4 based
blocking mechanisms, making the assessment SDF1-A specific
blocking of additional value; (2) both of these studies relied solely
on exogenous BSMCs, which may behave different than
endogenous cells; (3) neither of these studies evaluated the bone
marrow and blood response to cerebral ischemia, which is a
crucial component to understanding the overall pathway of
hematogenous-based stroke recovery mechanisms; and (4) both
of these studies used rat models of stroke. This last point is
particularly of interest, as Steiner et al. demonstrated no homing
of exogenously (IV) administered human MSCs in a murine model
of stroke, despite confirmation of cell migration to peripheral
organs. The relevance of these mechanisms to murine stroke is
crucial as most preclinical restorative therapy work has previously,
and currently continues, in mice.
The data contained in the current study suggest that brain tissue
of stroked mice does generate SDF1-A and thereby recruits Lin2/
Sca1+ cells along an SDF1-A gradient to the area of ischemic
brain. That cerebral infarct volume reduction, identified following
exogenous Lin2/Sca1+ cell administration, was abrogated when
Lin2/Sca1+ cell administration occurred concomitant to SDF1-A
antibody administration provides further support to this hypothesis
(Figure 4). While this effect may be secondary to unintended and
unaccounted for effects of the SDF1-A antibody, it appears likely
that the reduction in benefit was at least in part due to the
prevention of appropriate homing of the Lin2/Sca1+ cells along
the SDF1-A gradient. Previous investigators have demonstrated
improvement in stroke volumes with exogenous BSMC adminis-
tration, [36] however, the data contained herein provides crucial
evidence that homing occurs in a murine model, that it provides a
reduction in infarct volume, and is dependent on the SDF1-A
pathway.
Further support for an SDF1-A dependent pathway was
evidenced when SDF1-A antibody administration prevented
detection of significant numbers of Y chromosome positive
Lin2/Sca1+ cells in the brain, despite evidence of Y chromosome
Lin2/Sca1+ cell homing without the SDF1-A antibody (Figure 5).
These data lends further credence to the hypothesis that the
homing mechanism occurs through an SDF1-A dependent
pathway. This finding also implies that SDF1-A’s effect is not
limited to its potential role in mobilization from the bone marrow
Figure 3. Enumeration of bone marrow and blood Lin2/Sca1+ cell numbers following stroke and SDF1-A Antibody. (A) Twenty-four
hour post stroke+SDF1-A antibody mice show a marked increase in the number of Lin2/Sca1+ cells present in the bone marrow compared to
controls. (B) Twenty-four hour post stroke mice showed a marked decrease in the mobilization of these cells to the blood. * P,0.05.
doi:10.1371/journal.pone.0085615.g003
Figure 4. Administration of Lin2/Sca1+ cells post stroke. A. Administration of Lin2/Sca1+ cells post stroke significantly reduced infarct
volume at 24 hours post stroke (*P,0.05). B. Administration of the Lin2/Sca1+ cells with an SDF1-A antibody (AB) no longer demonstrates a
beneficial reduction in the infarct volume (p =NS).
doi:10.1371/journal.pone.0085615.g004
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to the blood, but also through a direct effect in guiding circulating
Lin2/Sca1+ cells homing to the ischemic brain, as the male
Lin2/Sca1+ cells were exogenously administered, and so should
not be subject to sequestration in the bone marrow. Male mice
were used for the initial portion of this study to avoid contribution
of the estrogen/estrogen receptor axis towards SDF1-A produc-
tion. However, female mice were utilized for this homing analysis
in order to facilitate tracking the Y chromosome positive cells in
the brain. It should be noted that gender differences exist with
respect to SDF1-A production, especially in cardiac reperfusion (I/
R) studies. Huang et al [44] showed that despite similar baseline
SDF1-A levels in male and female rats, the female rats had higher
levels of SDF1-A production following I/R. Subsequent interpre-
tation should be conscientious of this axis, however, it is our intent
to merely utilize the chromosome difference between genders as a
tool to provide some additional insight into SDF1-A mediation of
homing. Additionally, such cross gender analysis has been well
established in the stroke literature. [44,45].
In ischemic cardiovascular disease, SDF1-A therapy has led to
increased cell survival, neovascularization and tissue repair; [46]
Blocking the SDF1-A/CXCR4 axis with AMD3100 (a CXCR4
antagonist) has been shown to cause a decrease in the number of
cells homing to an area of injury and an exacerbated apoptotic cell
death. [47] In our study, SDF1-A was blocked using an anti-
SDF1-A antibody rather than using an antibody directed to its
receptor, CXCR4, as previously performed by Wang et al. [36]
SDF1-A has recently been shown to bind to another receptor,
CXCR7. [20] Blocking of the CXCR4 receptor alone provides a
potential alternative mechanism of effect for SDF1-A. Given
Wang et al. and Shichinohe et al.’s prior work it appears likely
that CXCR4 is crucial to the overall pathway, however, as they
did not evaluate blood and bone marrow for possible sequestra-
tion, it is possible that the peripheral effects we observed are due to
either CXCR4 or CXCR7. Further evaluation of the separate
SDF1-A receptors will better elucidate which of those receptors
play a critical role in the various components of post-stroke
homing.
Our results suggest that local incremental increases in SDF1-A
facilitate homing of Lin2/Sca1+ cells, and that neutralizing
SDF1-A with an antibody abolished the homing of Lin2/Sca1+
cells to stroked brain. Cerebral ischemia leads to an increase in
SDF1-A in the ischemic hemisphere, as well as increased
production of Lin2/Sca1+ cells in the bone marrow. These cells
then mobilize to the blood, apparently in response to an SDF1-A
gradient. Furthermore, SDF1-A appears to play a critical role in
modulating Lin2/Sca1+ cell migration to the site of the stroke
itself and that administration of an SDF1-A neutralizing antibody
impaired both the mobilization of Lin2/Sca1+ cells to the blood,
as well as the homing of exogenous Lin2/Sca1+ cells to ischemic
brain. These data suggest a critical role for SDF1-A following
cerebral ischemia; however further studies are required to more
clearly delineate the mechanisms by which SDF1-A exerts its
effects.
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